

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CHANGE OF JOINT COMPANY SECRETARY
AND
WAIVER FROM STRICT COMPLIANCE WITH
RULES 3.28 AND 8.17 OF THE LISTING RULES**

The board (the “**Board**”) of directors (the “**Directors**”) of HighTide Therapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that due to her need to devote more time on her other work commitments, Ms. YU Li (于莉) (“**Ms. Yu**”) has tendered her resignation as a joint company secretary of the Company (the “**Joint Company Secretary**”) with effect from December 19, 2024. Ms. Yu will remain as the vice president of the Group and the vice general manager of Shenzhen HighTide Biopharmaceutical Ltd. (a wholly-owned subsidiary of the Company) after her resignation as the Joint Company Secretary.

Ms. Yu has confirmed that she has no disagreement with the Board during her term of office as the Joint Company Secretary and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board would like to express its sincere gratitude to Ms. Yu for her contributions to the Company during her tenure as a Joint Company Secretary.

The Board also announces that Ms. GAO Liping (高麗萍) (“**Ms. Gao**”) has been appointed as a Joint Company Secretary (the “**Appointment of Ms. Gao**”) with effect from December 19, 2024, and she will jointly perform the duties of company secretary with Ms. CHU Pik Man (朱璧敏) (“**Ms. Chu**”), who is currently the other joint company secretary of the Company.

The biographical details of Ms. Gao and Ms. Chu are set out as follows:

Ms. Gao has been focusing on capital market and investor relations management over 15 years. Ms. Gao has been serving as the investor relations director of the Company since October 2022. Ms. Gao obtained a bachelor's degree in International Relations from Peking University (北京大學) in 2003, and a master degree in Business Administration from Aberdeen University of UK in 2004. She also obtained qualifications as a Certified Management Accountants of USA in June 2024.

Ms. Chu was appointed as one of the joint company secretaries of the Company on December 11, 2023. Ms. Chu is an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited. Ms. Chu obtained her bachelor's degree of business administration (honours) in corporate governance concentration from Hong Kong Shue Yan University in July 2018. Ms. Chu is an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

Waiver from Strict Compliance with Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) with respect to the Appointment of Ms. Gao

Pursuant to Rule 8.17 of the Listing Rules, a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Pursuant to Rule 3.28 of the Listing Rules, the company secretary must be an individual who, by virtue of his/her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of company secretary.

Given Ms. Gao currently does not possess the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules, therefore, the Company has made application to the Stock Exchange for and the Stock Exchange has granted a waiver (the “**Waiver**”) from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years (the “**Waiver Period**”) from the date of Appointment of Ms. Gao (i.e. December 19, 2024). The grounds for seeking the Waiver are (a) the Company, headquartered in Shenzhen, is a corporation which has principal business activities primarily outside Hong Kong. The principal activities of the Group are involved in research and development of pharmaceutical products in the PRC. As the Group's core business and operations are substantially based and conducted in the PRC, the Company believes that it is necessary to appoint Ms. Gao as a company secretary whose presence in the headquarters of the Group enables her to attend to the day-to-day corporate secretarial matters concerning the Group; (b) Ms. Gao has served as the investor relations director of the Company since October 2022; therefore she is familiar with the business operations of the Group. Prior to joining the Company, Ms. Gao had held relevant positions successively at the investor relations management sector of several companies, therefore is also well-equipped with knowledge in corporate governance, investor relations and capital market affairs of PRC companies; (c) the Board believes that from the perspective of talent development and retention in the long term, it would be the best for the Company to develop talent by organic growth within the

Company. Based on a comprehensive assessment on Ms. Gao's experience, knowledge and background, the Board believes that Ms. Gao, who has substantial experience and knowledge in corporate governance, capital market and investor relations management matters of the Group, with her participation in the listing process of the Group, collaboration with Ms. Yu in handling the affairs of the board of the Company, and her familiarity in the business operations and corporate culture of the Group, would make her a suitable candidate for acting as a company secretary of the Company; (d) Ms. Gao will also be assisted by the Hong Kong legal advisers of the Company, particularly in relation to Hong Kong corporate governance practices and compliance issues, on matters concerning the Company's ongoing compliance with the Listing Rules and other applicable laws and regulations; and (e) Ms. Chu, who meets all the requirements under Rules 3.28 of the Listing Rules, will assist Ms. Gao so that Ms. Gao is able to acquire the relevant knowledge and experience as required under the Listing Rules in order to discharge her functions as the company secretary of the Company. Ms. Chu will maintain regular contact with Ms. Gao, the Directors and the senior management of the Company. Ms. Gao will endeavor to attend relevant training courses on a regular basis to familiarise herself with the requirements of the Listing Rules.

Ms. Gao has also confirmed that she will comply with the annual professional training requirement under Rule 3.29 of the Listing Rules by attending no less than 15 hours of relevant professional training courses in each financial year.

The Waiver is granted on the conditions that: (i) Ms. Gao must be assisted by Ms. Chu during the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company. Before the expiration of the Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Ms. Gao, having had the benefit of Ms. Chu's assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of the company secretary under Rule 3.28 of the Listing Rules, such that a further waiver will not be necessary. In addition, the Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping

Executive Director and Chief Executive Officer

Hong Kong, December 19, 2024

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. Jin LI and Mr. HUNG Tak Wai as independent non-executive Directors.